Investigating the role of mutant p53 and MCL-1 in the sustained growth of MYC lymphomas and strategies for targeted therapy [ 2015 - 2018 ]

Research Grant

Researchers: Dr Gemma Kelly (Principal investigator) ,  Dr Kylie Mason

Brief description A large number of human cancers have abnormal expression of a protein called MYC, leading to rapid growth. We found that when another protein called MCL-1 was inactivated, the lymphomas regressed. Importantly, mutations in the tumour suppressor gene called p53 are frequently found in cancer cells and we noticed that this could reduce the dependency on MCL-1. We aim to investigate this further in this grant proposal, in part using a novel drug that targets MCL-1.

Funding Amount $AUD 616,940.70

Funding Scheme Project Grants

Notes Standard Project Grant